NO304891B1 - Steroidderivater for behandling av prostatahypertrofi - Google Patents

Steroidderivater for behandling av prostatahypertrofi

Info

Publication number
NO304891B1
NO304891B1 NO931401A NO931401A NO304891B1 NO 304891 B1 NO304891 B1 NO 304891B1 NO 931401 A NO931401 A NO 931401A NO 931401 A NO931401 A NO 931401A NO 304891 B1 NO304891 B1 NO 304891B1
Authority
NO
Norway
Prior art keywords
substituted alkyl
treatment
alkyl
steroid derivatives
prostate hypertrophy
Prior art date
Application number
NO931401A
Other languages
English (en)
Norwegian (no)
Other versions
NO931401L (no
NO931401D0 (no
Inventor
Koichi Kojima
Hitoshi Kurata
Koki Ishibashi
Takakazu Hamada
Hiroyoshi Horikoshi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO931401D0 publication Critical patent/NO931401D0/no
Publication of NO931401L publication Critical patent/NO931401L/no
Publication of NO304891B1 publication Critical patent/NO304891B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO931401A 1992-04-20 1993-04-16 Steroidderivater for behandling av prostatahypertrofi NO304891B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9981692 1992-04-20
JP32804392 1992-12-08

Publications (3)

Publication Number Publication Date
NO931401D0 NO931401D0 (no) 1993-04-16
NO931401L NO931401L (no) 1993-10-21
NO304891B1 true NO304891B1 (no) 1999-03-01

Family

ID=26440917

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931401A NO304891B1 (no) 1992-04-20 1993-04-16 Steroidderivater for behandling av prostatahypertrofi

Country Status (24)

Country Link
US (3) US5536714A (enExample)
EP (2) EP0567271B1 (enExample)
JP (1) JP2514778B2 (enExample)
KR (1) KR0146680B1 (enExample)
CN (2) CN1041095C (enExample)
AT (1) ATE154937T1 (enExample)
AU (1) AU656852B2 (enExample)
CA (1) CA2094300C (enExample)
CZ (2) CZ284206B6 (enExample)
DE (1) DE69311837T2 (enExample)
DK (1) DK0567271T3 (enExample)
ES (1) ES2105108T3 (enExample)
FI (1) FI931765A7 (enExample)
GR (1) GR3024896T3 (enExample)
HU (1) HU219579B (enExample)
ID (1) ID18576A (enExample)
IL (1) IL105478A (enExample)
MX (1) MX9302300A (enExample)
NO (1) NO304891B1 (enExample)
NZ (1) NZ247449A (enExample)
PH (1) PH31052A (enExample)
RU (2) RU2097387C1 (enExample)
TW (2) TW238312B (enExample)
ZA (1) ZA932732B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1259419B (it) * 1991-05-24 1996-03-18 Erba Carlo Spa Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
AU4291993A (en) * 1992-04-30 1993-11-29 Smithkline Beecham Corporation 17alpha and 17beta -substituted estra-1,3,5(10)-triene-3-carboxylic acid
US5683995A (en) * 1992-11-18 1997-11-04 Smithkline Beecham Corporation 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors
US5641765A (en) * 1992-11-18 1997-06-24 Smithkline Beecham Corporation 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase
GB9224148D0 (en) * 1992-11-18 1993-01-06 Smithkline Beecham Corp Compounds
ES2185666T3 (es) * 1993-09-03 2003-05-01 Smithkline Beecham Corp Formulacion estabilizada para comprimidos.
GB9324371D0 (en) * 1993-11-26 1994-01-12 Erba Carlo Spa Side chain fluoro substituted 3-carboxysteroids
GB9411103D0 (en) * 1994-06-03 1994-07-27 Smithkline Beecham Corp Compounds
GB9415183D0 (en) * 1994-07-28 1994-09-21 Erba Carlo Spa 3-carboxysteroids with a fluorinated side-chain
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
US6372712B1 (en) 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
JP4490689B2 (ja) * 2001-10-03 2010-06-30 メルク・シャープ・エンド・ドーム・コーポレイション アンドロゲン受容体調節剤としてのアンドロスタン１７β−カルボキサミド類
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
WO2003059267A2 (en) * 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US20050020550A1 (en) * 2003-04-29 2005-01-27 Morris David J. Selective testicular 11beta-HSD inhibitors and methods of use thereof
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US7604386B2 (en) * 2005-11-18 2009-10-20 Federal-Mogul World Wide, Inc Lamp assembly having a socket made from high temperature plastic
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2011004242A2 (en) * 2009-07-09 2011-01-13 Aurobindo Pharma Limited An improved process for the preparation of dutasteride
CN111362999B (zh) * 2020-03-16 2022-03-29 江苏联环药业股份有限公司 一种爱普列特杂质及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
NZ211145A (en) * 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4910226A (en) * 1987-04-29 1990-03-20 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors

Also Published As

Publication number Publication date
CN1041095C (zh) 1998-12-09
KR930021654A (ko) 1993-11-22
HU219579B (hu) 2001-05-28
GR3024896T3 (en) 1998-01-30
US5760025A (en) 1998-06-02
EP0567271A3 (en) 1994-11-23
KR0146680B1 (ko) 1998-08-01
ES2105108T3 (es) 1997-10-16
CN1083070A (zh) 1994-03-02
NO931401L (no) 1993-10-21
US5717088A (en) 1998-02-10
IL105478A0 (en) 1993-08-18
US5536714A (en) 1996-07-16
FI931765L (fi) 1993-10-21
MX9302300A (es) 1994-03-31
JPH06279487A (ja) 1994-10-04
DE69311837T2 (de) 1998-02-12
RU95101838A (ru) 1997-01-10
HK1000303A1 (en) 1998-02-20
HU9301155D0 (en) 1993-07-28
EP0567271B1 (en) 1997-07-02
CA2094300C (en) 2003-01-28
DE69311837D1 (de) 1997-08-07
FI931765A7 (fi) 1993-10-21
ZA932732B (en) 1993-10-28
NO931401D0 (no) 1993-04-16
TW238312B (enExample) 1995-01-11
PH31052A (en) 1998-02-03
AU3698493A (en) 1993-10-21
DK0567271T3 (da) 1998-02-16
CZ284206B6 (cs) 1998-09-16
CZ90097A3 (cs) 1998-07-15
JP2514778B2 (ja) 1996-07-10
ATE154937T1 (de) 1997-07-15
AU656852B2 (en) 1995-02-16
RU2097387C1 (ru) 1997-11-27
EP0725074A3 (en) 1996-11-20
CN1195666A (zh) 1998-10-14
EP0725074A2 (en) 1996-08-07
ID18576A (id) 1998-04-23
RU2114861C1 (ru) 1998-07-10
CZ283791B6 (cs) 1998-06-17
FI931765A0 (fi) 1993-04-19
EP0567271A2 (en) 1993-10-27
TW401420B (en) 2000-08-11
IL105478A (en) 1998-03-10
CZ67893A3 (en) 1994-01-19
CA2094300A1 (en) 1993-10-21
HUT64558A (en) 1994-01-28
NZ247449A (en) 1995-02-24

Similar Documents

Publication Publication Date Title
NO931401D0 (no) Steroidderivater for behandling av prostatahypertrofi, samt fremstilling og anvendelse derav
AU676884B2 (en) 1H-indole-3-acetamide sPLA2 inhibitors
AU8682191A (en) Azasteroid compounds for the treatment of prostatic hypertrophy, their preparation and use
ATE67503T1 (de) 17-beta-substituierte-4-aza-5-alpha-androstenon und ihre anwendung als 5-alpha-reduktaseinhibitoren.
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
RU93005334A (ru) Производные стероидов для лечения гипертрофии предстательной железы, способ их получения, использование, фармкомпозиция
AU9066498A (en) Substituted 6-alkylphenanthridines
CA2256609A1 (en) 5-aroylpyrrol-2-ylmethylarene derivatives as inhibitors of prostaglandin g/h synthase
UA66888C2 (uk) 3-тетрагідропіридин-4-іл індоли, спосіб їх отримання та спосіб лікування психічних розладів
AU2287499A (en) Azetidinecarboxamide derivatives for treating cns disorders
AU686104B2 (en) Substituted amidinonaphthyl ester derivatives
NO964522D0 (no) Fremgangmåte ved fremstilling av 5,6-dihydroksy-2-amino-1,2,3,4-tetrahydronaftalenderivater
AU7589298A (en) 5-{(heteroaryl)alkyl}-3-oxo-pyrido{1,2-(a)}benzimidazole-4-c arboxamide derivatives useful in treating central nervous system disorders
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
AU2178099A (en) Azetidinecarboxamide derivatives for treating cns disorders

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN OCTOBER 2003